Rewards of Tight Blood Pressure Control Outweigh Risks, Trial Finds

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 21, 2025.

By Dennis Thompson HealthDay Reporter

FRIDAY, Feb. 21, 2025 -- The health benefits of aggressive blood pressure control outweigh the potential risks for seniors, according to the latest results from a major clinical trial.

About 85% of seniors treated to a target blood pressure of 120 systolic (the top number in a blood pressure reading) had a positive net benefit from such tight control, researchers reported.

The reduced risk of heart disease and early death outweighed the negatives that can accompany such aggressive treatment, which include potential kidney damage or dangerously low blood pressure, results show.

“Almost all … participants aged 65 years or greater had a predicted net benefit that favored an systolic blood pressure target of less than 120 mm Hg over a systolic blood pressure target of less than 140 mm Hg,” concluded the research team led by senior investigator Dr. Simon Ascher, an assistant clinical professor with the University of California-Davis.

Systolic blood pressure refers to pressure within blood vessels during a heartbeat.

Elderly patients, frail seniors and those taking many different medications derived "greater absolute harms from intensive blood pressure lowering," along with greater heart disease, cognitive and death rate benefits, the study found.

These results come from the Systolic Blood Pressure Intervention Trial (SPRINT), which in 2017 led major U.S. cardiology groups to revise their definition of high blood pressure.

As a result, blood pressure of 130 systolic has been considered “high” for the past eight years, down from a target of lower than 140 systolic prior to the release of the first SPRINT results.

Normal blood pressure is considered less than 120 systolic, while anything between 120 and 130 is considered elevated but not yet high blood pressure.

For the new study, researchers conducted more in-depth analysis of more than 5,100 SPRINT participants 65 and older, comparing those assigned to aggressive treatment against those treated to a target of 140 systolic.

“These findings indicate that when accounting for an individual's estimated risks and outcome preferences, the benefits of intensive BP lowering outweigh the harms for most SPRINT-eligible, community-dwelling older adults with hypertension, especially among high-risk subgroups who are often assumed to neither tolerate nor benefit from intensive BP lowering,” researchers concluded.

The results are particularly important given that most Americans have poorly controlled blood pressure, the research team said.

“Less than half of U.S. adults aged 65 years or greater with a hypertension diagnosis have well-controlled BP, defined as BP less than 130/80 mm Hg,” the researchers wrote.

Part of the problem is that doctors have been reluctant to strictly treat high blood pressure among patients who are elderly, frail and taking a number of medications, researchers said.

“Our findings suggest that, contrary to conventional wisdom, factors such as age, frailty, or polypharmacy should not be viewed as barriers to intensive BP lowering,” the team concluded.

The new study was published Feb. 18 in the Journal of the American Geriatrics Society.

Sources

  • American Geriatrics Society, news release, Feb. 19, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-02-22 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords